Press Release November 17, 2017

Alnylam Pharmaceuticals Closes $805 Million Public Offering

The Life Sciences team advised Alnylam Pharmaceuticals [NASDAQ: ALNY] on its public offering totaling $805 million in gross proceeds from the sale of 6,440,000 shares of common stock at a price of $125.00 per share, which included the full exercise of the underwriters’ option to purchase additional shares.
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
The Goodwin team was led by partners Mitch Bloom and Gregg Katz and included associates Will Goldberg and Chloe Pletner.
For more information on the offering, please read the press release.